<DOC>
	<DOCNO>NCT01921829</DOCNO>
	<brief_summary>This research study randomize clinical trial evaluate take diuretic ( medication increase urine production help fluid removal body ) standardize fashion ( use guideline adjust dos base measured urine output ) could improve health outcome patient cardiorenal failure cardiorenal syndrome ( combined heart kidney failure ) edema ( much fluid arm , leg , and/or lung ) . Under usual care , patient treat diuretic medication increase dos , necessarily maintain specific amount urine output per day . Current heart failure ( HF ) treatment guideline provide standard protocol , guideline , adjust diuretic dos . At point kidney function worsen degree kidney longer able respond medication use remove fluid , either ultrafiltration ( UF ) dialysis ( also call hemodialysis [ HD ] ) typically start order remove fluid . In UF dialysis , excess fluid remove body use machine . In dialysis , waste product fluid remove electrolyte abnormality correct . In UF , fluid remove . Both procedure use machine . This study test whether Protocolized Diuretic Strategy ( ProDiuS ) , plan adjust diuretic dos base measured urine output , improve clinical care cardiorenal syndrome . Such plan adjust diuretic dos need improve symptom , decrease length hospital stay rehospitalization rate , improve health-related quality life ( HRQOL ) cardiorenal syndrome patient .</brief_summary>
	<brief_title>Protocolized Diuretic Strategy Cardiorenal Failure</brief_title>
	<detailed_description>Heart failure ( HF ) account 1 million hospital admission annually United States lead cause disability healthcare cost . Cardiorenal syndrome worsen renal function independent risk factor morbidity mortality HF . Effective fluid removal , manifest decrease body weight , one important goal treatment cardiorenal syndrome . Current medical therapeutic option , include sodium fluid restriction , diuretic , blockade renin-angiotensin-aldosterone system , inotropes , nesiritide , suboptimal patient advance cardiorenal syndrome . When medical therapy fail , ultrafiltration ( UF ) may use mechanical fluid removal use dialysis UF machine . UF effectively remove fluid HF patient , precise role therapy cardiorenal syndrome still unclear . A multicenter randomize control trial ( CARRESS-HF ) suggest UF superior step pharmacologic diuretic regimen , similar amount weight loss two approach high rate adverse event UF group . Therefore , protocolized diuretic strategy need superior current clinical care management cardiorenal syndrome . Current HF guideline provide standard protocol diuretic dosing . The variation usual clinical care may explain long hospital stay worsen renal function common patient . One retrospective observational study compare diuretic dose protocol usual diuretic therapy patient admit acute decompensated HF . Protocol diuretic use associate great weight loss significantly low risk 30-day readmission . However , due retrospective design , baseline characteristic two group differ many pertinent covariates , generalizability limit . The propose study aim determine protocolized diuretic treatment strategy , oppose usual clinical care , result improve clinical decongestion , clinical outcome , health-related quality life ( HRQOL ) , preserve renal function hospitalize patient cardiorenal syndrome . It prospective randomize single-blind trial equal allocation ( 1:1 ) random block randomization 150 participant hospitalize University Pittsburgh Medical Center ( UPMC ) cardiorenal syndrome recruit 3 year ( approximately 50 participants/year ) . Participants cardiorenal syndrome randomize Protocolized Diuretic Strategy ( base step pharmacologic algorithm use CARRESS-HF trial ) vs. Usual Care . Participants follow daily hospital treatment period , well 1-month 3-month follow-up visit outpatient HF clinic . Primary Research Question : 1 . In hospitalized patient cardiorenal syndrome , protocolized diuretic treatment strategy , oppose usual clinical care , result improve clinical decongestion base change body weight day 4 hospital discharge ( whichever come first ) ? Primary Hypothesis . In hospitalized patient cardiorenal syndrome , protocolized diuretic therapy result great reduction body weight improved clinical decongestion compare usual care . Secondary Research Questions : 1 . Do clinical outcome , include length hospitalization , number rehospitalizations HF , mortality , improve protocolized diuretic therapy compare usual care 3 month ? Hypothesis 1 . Protocolized diuretic therapy associate reduced length hospital stay , decrease rehospitalization rate , decreased mortality , compare usual care . 2 . Do measure volume status improve protocolized diuretic therapy compare usual care hospitalization 3 month ? Hypothesis 2 . Protocolized diuretic therapy associate great decongestion base increase venous compliance internal jugular vein ( via Doppler ultrasound ) , negative fluid balance , clinical decongestion , compare usual care . 3 . Do HRQOL outcomes improve protocolized diuretic therapy compare usual care 3 month ? Hypothesis 3 . HRQOL indices physical well-being , mental well-being , sleep quality domain improve protocolized diuretic therapy compare usual care . 4 . Do renal outcome ( safety endpoint ) , include renal function change need UF renal replacement therapy , differ protocolized diuretic therapy usual care hospitalization 3 month ? Hypothesis 4 . Protocolized diuretic therapy superior usual care term worsen renal function need UF renal replacement therapy . Subgroup Research Questions : 1 . Do outcome differ Protocolized Diuretic Strategy vs. Usual care stratify type heart failure ( e.g. , systolic dysfunction ( EF &lt; 40 % ) vs. diastolic dysfunction ( EF ≥40 % ) ; ischemic vs. ; none-mild vs. moderate-severe mitral regurgitation ( MR ) tricuspid regurgitation ( TR ) ) ? Hypothesis 1 . No difference see treatment control group base type heart failure . This trial utmost interest cardiologist nephrologists , struggle find optimal diuretic medical management strategy effectively remove excess fluid yet preserve renal function . It highly relevant many clinician community large , HF cardiorenal syndrome lead cause hospitalization healthcare cost . If protocolized diuretic strategy find optimally remove fluid efficient safe manner , could potentially disseminate community physician and/or incorporate public policy HF treatment guideline order improve quality care reduce healthcare cost population high morbidity mortality .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
	<criteria>Age ≥21 year History heart failure ( HF ) , either leave ventricular ( LV ) dysfunction ( EF &lt; 40 % ) least stage I diastolic right ventricular ( RV ) dysfunction base echocardiogram ( ECHO ) within last year diagnosis HF International Classification Diseases ( ICD9 ) Evidence renal dysfunction base one follow : Estimated glomerular filtration rate ( GFR ) 1559 mL/min/1.73 m2 base Modification Diet Renal Disease ( MDRD ) equation use serum creatinine ( Cr ) obtain within 6 month admission Elevated Cr upper limit normal An increase serum Cr ≥0.3 mg/dL ≥50 % baseline admission diuretic therapy , alternative cause worsen renal function , demonstrate sign symptoms persistent volume overload occur within 7 day admission hospitalization Evidence volume overload clinical and/or radiographic feature , least 2 follow : 1 ) peripheral edema ≥2+ ; 2 ) jugular venous distension ≥7 cm ; 3 ) radiographic pulmonary edema pleural effusion ; 4 ) enlarge liver ascites ; 5 ) pulmonary rale , paroxysmal nocturnal dyspnea , orthopnea ; 6 ) elevate brain natriuretic peptide ( BNP ) level ; 7 ) documentation elevate right heart fill pressure pulmonary artery catheter right heart catheterization Use inotropes ( time screen ) Acute indication hemodialysis ( HD ) ( e.g. , severe hyperkalemia , metabolic acidosis , uremic sign symptom , pericardial friction rub ) Specific form HF chart diagnosis : 1 . Congenital heart disease 2 . Primary valvular heart disease due severe valvular stenosis acute severe valvular regurgitation valvular disease require immediate surgical repair 3 . Infiltrative cardiomyopathy 4 . Pulmonary hypertension ( PH ) define World Health Organization ( WHO ) group I WHO group IV Prior use ultrafiltration ( UF ) HD 3 month precede hospitalization Endstage renal disease ( ESRD ) require chronic dialysis estimate GFR &lt; 15 mL/min/1.73 m2 MDRD equation ( i.e. , preexist ESRD ) Prior cardiac kidney transplantation Intravascular volume depletion base clinical assessment Cardiogenic shock and/or systolic blood pressure ( SBP ) &lt; 90 mmHg Unstable coronary disease acute coronary syndrome within 1 month admission Alternative explanation worsen renal function ( e.g. , obstructive nephropathy , contrastinduced nephropathy , acute tubular necrosis , intrinsic renal disease ) Life expectancy &lt; 3 month due chronic health condition ( e.g. , endstage liver disease , pulmonary disease , malignancy , etc . ) Psychiatric disorder require admission psychiatric hospital HF admission Previous enrollment trial diuretic UF trial prior 3 month Expected geographic unavailability 3 month follow hospital admission Pregnancy Inability provide inform consent Physician 's assessment use protocol could unsafe lead adverse consequence patient</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Cardiorenal failure</keyword>
	<keyword>Cardiorenal syndrome</keyword>
	<keyword>Diuretic resistance</keyword>
	<keyword>Volume overload</keyword>
	<keyword>Edema</keyword>
	<keyword>Health-related quality life</keyword>
	<keyword>Outcomes</keyword>
	<keyword>Treatment protocol</keyword>
</DOC>